title: Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast.
abstract: BACKGROUND
  To better understand the mechanisms of the SDC1 expression in invasive ductal carcinoma, we studied the correlations between SDC1 expression and related gene expressions (RSPO1, WNT1, WT1, and P16).
  
  
  METHODS
  Using 100 cases of invasive ductal carcinoma tissue, we screened expressions of RSPO1, WNT1, WT1, P16, and SDC1 using immunohistochemistry. We analyzed the association between the immunoreactivities and clinicopathological parameters.
  
  
  RESULTS
  WT1 expression was associated with tumor grade. RSPO1 expression was associated with progesterone receptor expression. Expressions of RSPO1, WT1, and P16 were significantly associated with disease-free survival. RSPO1 and P16 showed statistically significant hazard ratios. SDC1 ectodomain expression was significantly associated only with P16 expression. Immunoreactivity of SDC1 cytoplasmic domain was associated with WT1 and WNT1. However, WNT1 expression failed to show a significant association with disease-free survival.
  
  
  CONCLUSIONS
  RSPO1 and P16 immunoreactivity was found to be an independent prognostic indicator in invasive ductal cancer. Cytoplasmic expression of SDC1 is positively correlated with tumor-prone proteins (WT1 and WNT1) and membranous expression of SDC1 is positively correlated with the tumor suppressor (P16).
authors.forename: Eun Ji
authors.initials: EJ
authors.lastname: Choi
authors.forename: Jeong A
authors.initials: JA
authors.lastname: Yun
authors.forename: Eun Kyoung
authors.initials: EK
authors.lastname: Jeon
authors.forename: Hye Sung
authors.initials: HS
authors.lastname: Won
authors.forename: Yoon Ho
authors.initials: YH
authors.lastname: Ko
authors.affiliation: Department of Pathology, The Catholic University of Korea, School of Medicine, Seochogu Banpodaero 222, Seoul 137-701, Republic of Korea. suyoung@catholic.ac.kr.
authors.forename: Su Young
authors.initials: SY
authors.lastname: Kim
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D053668:Syndecan-1 / Q000378:metabolism*; D019699:Thrombospondins / Q000378:metabolism*; D025721:WT1 Proteins / Q000378:metabolism*; D051155:Wnt1 Protein / Q000378:metabolism*; D000098907:R-Spondins
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D053668:Syndecan-1; D019699:Thrombospondins; D025721:WT1 Proteins; D051155:Wnt1 Protein; C000614131:CDKN2A protein, human; C503243:RSPO1 protein, human; D000098907:R-Spondins; C508241:SDC1 protein, human; C495247:WNT1 protein, human